ArticleVirchows Archiv. A, Pathological anatomy and histopathology1992
Paraffin section immunohistochemistry in the diagnosis of Hodgkin's disease and anaplastic large cell (CD30+) lymphomas.
Article in Virchows Archiv. A, Pathological anatomy and histopathology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 40 citations in OpenAlex.
- CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.The American journal of pathology · 1996Article
- CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.The American journal of pathology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphological and immunohistological studies were carried out on a series of 137 lymphomas including CD30+ anaplastic large cell (ALC) lymphomas (48 cases) and non-lymphocyte predominant Hodgkin's disease (HD) (89 cases), with the aim of assessing in situ expression of a combination of antibodies including anti-CD30/BerH2, epithelial membrane antigen (EMA), CD15 and CD45, in addition to other monoclonal antibodies suitable for paraffin tissues. A greater proportion of cases of ALC lymphomas than of HD exhibited positivity for CD45 (91.7% vs 17.6%), EMA (56.2% vs 4.5%), CD43 (53.6% vs 13.1%) and CD45RO (39.5% vs 3.5%), whereas Reed-Sternberg (RS) cells in HD most frequently expressed CD15 (93.2% vs 20.8%) antigen. Moreover, in 35 of 48 (72.9%) ALC lymphomas tumour cells expressed the CD30+, CD45+, CD15-, EMA- or + phenotypic profile, while in the same percentage (62/85) of HD cases RS cells were found to express the CD30+, CD45-, CD15+, EMA- profile. This study suggests that the differential expression of CD45, EMA, and CD15 may be used in the separation of ALC lymphomas and HD. However, co-expression of CD30, CD45 and CD15 antigens by RS cells in HD (14/85 cases, 16.5% in this series) and by tumour cells in ALC lymphomas (9/48 cases, 18.7% in this series) may be encountered in a non-negligible fraction of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.